Overview Quote
Stock Activity
| Day Low - High | 63.30 - 65.30 |
| 52wk Low - High | 34.30 - 71.56 |
| Previous Close | 64.50 |
| Avg. Volume | 1,341,113 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 8.07 B |
| Div - Yield | 0.00 - 0.00 |
| Beta | 1.24 |
| PE (Forward) | 0.00 |
| Current Year Est. | -1.25 |
| Quarterly Earnings ESP |
3.45% |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
91 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Company Description
BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.29 | -0.33 | -1.25 | -0.70 |
| Number of Estimates | 12 | 12 | 15 | 13 |
| Low Estimate | -0.34 | -0.45 | -1.44 | -1.46 |
| High Estimate | -0.23 | -0.24 | -1.00 | NA |
| Year Ago EPS | -0.27 | -0.04 | -0.95 | -1.25 |
| EPS Growth | -5.86% | -716.67% | -31.93% | 44.21% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| BIOMARIN PHARMA | BMRN | 64.01 | ![]() |
![]() |
| AETERNA ZENTARS | AEZS | 2.10 | ![]() |
![]() |
| ANIKA THERAPEUT | ANIK | 14.40 | ![]() |
![]() |
| GENTIUM SPA-ADR | GENT | 8.87 | ![]() |
![]() |
| AASTROM BIOSCI | ASTM | 0.57 | ![]() |
![]() |
| ACHILLION PHARM | ACHN | 7.77 | ![]() |
![]() |
| ADDEX THERA LTD | ADDXF | 6.94 | ![]() |
![]() |
| AFFYMAX INC | AFFY | 1.33 | ![]() |
![]() |
| ALEXION PHARMA | ALXN | 102.90 | ![]() |
![]() |
| ALKERMES INC | ALKS | 31.69 | ![]() |
![]() |
Sector:Medical>> Industry:MED-BIOMED/GENE
Zacks Commentary
BioMarin Widens Loss, Maintains View
Apr 29, 2013
BioMarin Attains 52-Week High
Apr 11, 2013
BioMarin Files CTA for BMN-190
Apr 03, 2013
BMRN Seeks US Approval of Vimizim
Apr 02, 2013
Data on BioMarin's BMN-701
Mar 21, 2013
BioMarin Reports Wider Loss
Feb 22, 2013
Positive Data from BMRN's PKU-016
Feb 20, 2013
BioMarin Takes Over Zacharon
Jan 10, 2013
Financials
| EPS TTM | -1.05 |
| Sales | 501 |
| Net Income | -130 |
| Price/Earnings | NA |
| Price/Book | 6.46 |
| Price/Cash Flow | NA |
| Price/Sales | 15.77 |
News
BioMarin Announces BMN-673 Data in Breast and Ovarian Cancers to be Released at ASCO - Globenewswire
May 16, 2013
BioMarin Pharmaceutical Makes a Move: Down 5.4% - Financial News Network Online - Market Movers
May 16, 2013
BioMarin Pharmaceutical's Shares Changing Hands at Lower Prices on 1.5x Above-Average Volume (BMRN) - Financial News Network Online - Unusual Volume
May 16, 2013
10 ASCO `13 Abstracts You Can Read Right Now - TheStreet.com
May 15, 2013
BioMarin Pharmaceutical (BMRN) Could Fall Through $66.53 Support Level - Freshbrewedmedia
May 14, 2013
BioMarin to Present at the UBS Global Healthcare Conference - Globenewswire
May 14, 2013
Buyers Accumulate Shares of BioMarin Pharmaceutical, Up 1.9% - Financial News Network Online - Market Movers
May 13, 2013
Shares of BioMarin Pharmaceutical Have Risen Above Previous 52-Week High - Financial News Netwfork Online - 52-Week High-Lows
May 13, 2013
Broker Recommendations
| Current ABR | 1.53 |
| ABR (Last Week) | 1.53 |
| # of recs in ABR | 17 |
| Average Target Price | 67.87 |
| Industry Rank by ABR | 91 out of 265 |
| Rank in Industry | 36 out of 155 |

